Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,728 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $146.41, for a total value of $692,226.48. Following the transaction, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $468,111.60.
• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total value of $645,483.52.

Natera Stock Performance

Shares of NASDAQ NTRA traded down $5.05 during trading on Friday, reaching $146.06. 2,242,126 shares of the company traded hands, compared to its average volume of 1,338,689. The firm has a 50 day simple moving average of $127.38 and a 200-day simple moving average of $115.46. Natera, Inc. has a 52-week low of $52.01 and a 52-week high of $167.79. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the previous year, the company posted ($0.95) earnings per share. The firm’s revenue was up 63.9% on a year-over-year basis. Equities research analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on NTRA shares. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. JPMorgan Chase & Co. increased their price objective on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.65.

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Wellington Management Group LLP lifted its position in Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after buying an additional 1,883,481 shares during the period. Farallon Capital Management LLC raised its stake in Natera by 13.6% during the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares in the last quarter. First Light Asset Management LLC increased its position in shares of Natera by 295.9% during the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after purchasing an additional 490,822 shares during the period. AQR Capital Management LLC increased its position in shares of Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock valued at $70,553,000 after purchasing an additional 469,327 shares during the period. Finally, PointState Capital LP grew its holdings in shares of Natera by 112.0% in the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after acquiring an additional 413,468 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.